OLMA

Olema Pharmaceuticals Inc

7.00

Oct 30 • 3:59 PM ET -0.33 (-4.50%)

7.00

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: ARVN CELC RLAY LLY AZN PFE ATOS IDYA ELVN NVS

| Held by: VTI XBI IWM VXF IWN DFAS IBB VTWO FESM SCHA

Scroll to Statements

Index	RUT
Market Cap	612.48M
Enterprise Value	155.07M
Income	-204.57M
Sales	0.00M
Book/sh	4.92
Cash/sh	5.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	131
IPO	Nov 19, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.42
P/C	1.33
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.86
Current Ratio	8.86
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.12
EPS next Y	-2.66
EPS next Q	-0.64
EPS this Y	-28.05%
EPS next Y	-11.21%
EPS next 5Y	-6.23%
EPS past 3/5Y	10.68% -25.06%
Sales past 3/5Y	- -
EPS Y/Y TTM	-10.16%
Sales Y/Y TTM	-
EPS Q/Q	-18.14%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-10.61% -

Insider Own	19.66%
Insider Trans	-0.15%
Inst Own	100.64%
Inst Trans	0.56%
ROA	-47.10%
ROE	-52.74%
ROIC	-47.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.25%
SMA50	-20.79%
SMA200	-50.10%
Trades

Shs Outstand	87.45M
Shs Float	70.29M
Short Float	22.31%
Short Ratio	13.29
Short Interest	15.68M
52W High	36.26 -80.69%
52W Low	6.24 12.27%
Volatility	8.15% 6.75%
ATR (14)	0.51
RSI (14)	39.92
Beta	2.10
Rel Volume	0.64
Avg Volume	1.18M
Volume	751,366

Perf Week	9.20%
Perf Month	-15.36%
Perf Quarter	-37.94%
Perf Half Y	-51.12%
Perf YTD	-72.00%
Perf Year	-20.27%
Perf 3Y	-47.21%
Perf 5Y	-74.07%
Perf 10Y	-
Recom	1.17
Target Price	36.50
Prev Close	7.33
Price	7.00
Change %	-4.50%

Consensus

Strong Buy

Avg. Price Target

$36.50

Implied Upside

+421.4%

Analysts14incl. previous ratings

Rating Distribution13 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 27, 2026	Initiated	WWolfe Research	Peer Perform
Mar 19, 2026	Resumed	JJefferies	Buy
Feb 11, 2026	Initiated	SStifel	Buy	$48	+585.7%
Jan 07, 2026	Initiated	PPiper Sandler	Overweight	$40	+471.4%
Oct 08, 2025	Initiated	GGuggenheim	Buy	$20	+185.7%
Aug 12, 2025	Reiterated	CCitigroup	Buy	$20 → $21	+200.0%
Apr 02, 2024	Initiated	GGoldman	Buy	$24	+242.9%
Jan 30, 2024	Initiated	CCitigroup	Buy	$20	+185.7%
Jul 21, 2023	Initiated	OOppenheimer	Outperform	$21	+200.0%
May 05, 2023	Initiated	CCapitalOne	Overweight	$16	+128.6%
Feb 22, 2023	Initiated	CCredit Suisse	Outperform	$12	+71.4%
Jul 06, 2022	Resumed	CCanaccord Genuity	Buy	$16	+128.6%
Jun 09, 2022	Upgrade	HH.C. Wainwright	Neutral → Buy	$12	+71.4%
Feb 28, 2022	Initiated	HH.C. Wainwright	Neutral
Dec 07, 2021	Resumed	CCowen	Outperform
Dec 14, 2020	Initiated	JJP Morgan	Overweight	$52	+642.9%
Dec 14, 2020	Initiated	JJefferies	Buy	$70	+900.0%
Dec 14, 2020	Initiated	CCowen	Outperform
Dec 14, 2020	Initiated	CCanaccord Genuity	Buy	$60	+757.1%

Oct-02-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-26 08:10AM	Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results (InvestorsHub)
07:41AM	Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump (Investing.com)
Sep-02-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-31-26 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-13-26 07:00AM	Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer (GlobeNewswire)
Aug-10-26 04:01PM	Olema Oncology Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire) -12.65%
Aug-04-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.89%
May-26-26 07:00AM	Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
May-22-26 09:06AM	Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study (Stocktwits)
May-21-26 05:00PM	Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting (GlobeNewswire)
May-19-26 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.56%
May-12-26 07:00AM	Olema Oncology Reports First Quarter 2026 Financial and Operating Results (GlobeNewswire) -5.99%
04:30PM	Loading…
May-04-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-26 04:01PM	Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors (GlobeNewswire)
Apr-21-26 04:01PM	Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-17-26 04:01PM	Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting (GlobeNewswire)
Apr-02-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-17-26 04:30PM	Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting (GlobeNewswire) -9.31%
Mar-16-26 07:00AM	Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire) +12.85%
Mar-09-26 12:22PM	Why Is Olema Pharmaceuticals Stock Dropping On Monday? (Benzinga) -25.75%
11:15AM	Roche Tumbles, Taking Olema With It, On A High-Profile Failure (Investor's Business Daily)
Mar-03-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-26 03:05AM	Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference (MarketBeat)
Feb-27-26 04:05PM	Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure (Insider Monkey)
Feb-24-26 04:39AM	Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit (MarketBeat)
Feb-19-26 04:30PM	Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +6.25%
Feb-16-26 12:23PM	Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating (Insider Monkey)
01:02PM	Loading…
Feb-14-26 01:02PM	Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit (MarketBeat)
Feb-04-26 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Feb-03-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-26 04:01PM	Olema Oncology Announces Departure of Chief Operating and Financial Officer (GlobeNewswire)
09:47AM	LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) (Insider Monkey)
Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks)
Jan-05-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:19AM	Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT (Insider Monkey)
Dec-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 05:45PM	This strategist is 'following the money' on these stock picks (Yahoo Finance Video) +8.11%
Nov-21-25 04:30PM	Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.27%
Nov-20-25 04:01PM	Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.28%
Nov-19-25 11:50AM	Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? (Barchart)
07:00AM	Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock (GlobeNewswire)
Nov-18-25 04:51PM	Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +136.38%
04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
09:20AM	Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% (Investor's Business Daily)
Nov-10-25 07:00AM	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
Oct-30-25 04:30PM	Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 (GlobeNewswire)
Oct-18-25 03:00AM	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 (GlobeNewswire)
Oct-16-25 04:33PM	Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential (Insider Monkey) -7.43%
Oct-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 11:41AM	Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) (Insider Monkey)
Sep-12-25 10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
Sep-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 07:00AM	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer (GlobeNewswire) +18.50%
Aug-20-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-13-25 01:15AM	Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals (Insider Monkey)
Aug-11-25 04:01PM	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire) +16.19%
Aug-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.43%
May-28-25 07:00AM	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting (GlobeNewswire)
May-21-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? (Zacks)
May-13-25 04:01PM	Olema Oncology Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
Apr-25-25 01:00PM	Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 (GlobeNewswire)
Apr-24-25 09:55AM	Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet (Zacks)
Apr-10-25 09:35AM	After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) (Zacks) +8.25%
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 04:31PM	Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-18-25 04:01PM	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire) -6.97%
Mar-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Jul 24 '26	Sale	11.71	12,500	146,425	702,770	Jul 27 07:30 PM
Harmon Cyrus	Director	Jul 23 '26	Sale	11.58	12,500	144,738	715,270	Jul 27 07:30 PM
Harmon Cyrus	Director	Jul 24 '26	Proposed Sale	11.71	12,500	146,419		Jul 24 03:11 PM
Harmon Cyrus	Director	Jul 23 '26	Proposed Sale	11.58	12,500	144,738		Jul 23 02:23 PM
Kovacs Shane William Charles	Former Officer	Mar 16 '26	Proposed Sale	16.61	4,166	69,178		Mar 16 04:03 PM
Kovacs Shane William Charles	Former Officer	Mar 16 '26	Proposed Sale	16.08	100,000	1,607,719		Mar 16 12:43 PM
Kovacs Shane William Charles	Former Officer	Mar 11 '26	Proposed Sale	15.94	50,000	796,796		Mar 11 04:20 PM
Kovacs Shane William Charles	Former Officer	Mar 10 '26	Proposed Sale	17.00	53,206	904,566		Mar 10 12:27 PM
Kovacs Shane William Charles	Former Officer	Mar 09 '26	Proposed Sale	13.45	241,999	3,254,933		Mar 09 03:16 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Option Exercise	4.37	25,000	109,250	25,000	Mar 05 08:00 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Option Exercise	4.37	15,000	65,550	15,000	Mar 05 08:00 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Sale	24.25	25,000	606,353	0	Mar 05 08:00 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Sale	23.01	15,000	345,150	0	Mar 05 08:00 PM
Kovacs Shane William Charles	Former Officer	Mar 04 '26	Proposed Sale	24.43	20,000	488,654		Mar 04 02:19 PM
Mitchell Shawnte	Officer	Mar 04 '26	Proposed Sale	23.94	25,000	598,500		Mar 04 10:21 AM
Mitchell Shawnte	Officer	Mar 03 '26	Proposed Sale	23.01	15,000	345,153		Mar 03 02:59 PM
Kovacs Shane William Charles	Former Officer	Feb 27 '26	Proposed Sale	25.00	6,521	163,026		Feb 27 04:38 PM
Kovacs Shane William Charles	Former Officer	Feb 24 '26	Proposed Sale	25.00	20,000	500,002		Feb 24 03:46 PM
Kovacs Shane William Charles	Former Officer	Feb 23 '26	Proposed Sale	24.30	10,000	243,000		Feb 23 04:33 PM
Kovacs Shane William Charles	Former Officer	Feb 23 '26	Proposed Sale	24.00	20,000	480,007		Feb 23 02:34 PM
Kovacs Shane William Charles	Former Officer	Feb 12 '26	Proposed Sale	23.85	10,000	238,498		Feb 12 02:55 PM
Harmon Cyrus	Director	Jan 20 '26	Sale	26.88	10,000	268,800	727,770	Jan 21 09:00 PM
Harmon Cyrus	Director	Jan 20 '26	Proposed Sale	26.88	10,000	268,763		Jan 20 04:13 PM
Harmon Cyrus	Director	Jan 14 '26	Sale	29.12	3,489	101,600	737,770	Jan 16 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 15 '26	Sale	28.73	100,000	2,873,000	139,727	Jan 15 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 13 '26	Sale	28.01	3,822	107,054	239,727	Jan 15 09:00 PM
Kovacs Shane William Charles	Officer	Jan 15 '26	Proposed Sale	28.73	100,000	2,873,215		Jan 15 04:22 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Sale	28.87	50,000	1,443,651	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Sale	27.60	50,000	1,380,178	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 12 '26	Sale	28.34	10,000	283,400	144,846	Jan 14 09:30 PM
Harmon Cyrus	Director	Jan 14 '26	Proposed Sale	29.12	3,489	101,603		Jan 14 04:20 PM
Myles David C.	Officer	Jan 14 '26	Proposed Sale	28.87	50,000	1,443,631		Jan 14 04:13 PM
Kovacs Shane William Charles	Officer	Jan 13 '26	Proposed Sale	28.01	3,822	107,069		Jan 13 04:49 PM
Myles David C.	Officer	Jan 13 '26	Proposed Sale	27.60	50,000	1,380,113		Jan 13 04:12 PM
Myles David C.	Officer	Jan 12 '26	Proposed Sale	28.34	10,000	283,363		Jan 12 12:53 PM
Harmon Cyrus	Director	Dec 22 '25	Sale	28.53	2,881	82,195	741,259	Dec 29 09:55 PM
CLARK IAN T	Director	Dec 19 '25	Option Exercise	4.61	264,800	1,219,544	264,800	Dec 23 09:42 PM
CLARK IAN T	Director	Dec 19 '25	Sale	29.73	264,800	7,873,109	0	Dec 23 09:42 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 19 '25	Sale	30.46	51,000	1,553,544	551,881	Dec 23 09:41 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Option Exercise	14.07	50,000	703,392	153,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Option Exercise	15.25	40,000	610,000	173,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Option Exercise	7.02	50,000	351,000	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Sale	28.04	100,000	2,804,000	53,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Sale	27.66	99,509	2,752,419	4,488	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Sale	28.20	70,000	1,973,729	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Officer	Dec 23 '25	Proposed Sale	27.66	99,509	2,752,165		Dec 23 01:31 PM
Harmon Cyrus	Officer	Dec 22 '25	Proposed Sale	28.53	2,881	82,182		Dec 22 04:09 PM
Zojwalla Naseem	Officer	Dec 22 '25	Proposed Sale	28.04	100,000	2,804,039		Dec 22 02:14 PM
Myles David C.	Officer	Dec 19 '25	Proposed Sale	30.46	51,000	1,553,447		Dec 19 04:33 PM
Zojwalla Naseem	Officer	Dec 19 '25	Proposed Sale	28.19	70,000	1,973,561		Dec 19 04:29 PM
CLARK IAN T	Director	Dec 19 '25	Proposed Sale	29.73	264,800	7,873,502		Dec 19 02:35 PM
RAPPAPORT ANDREW	Director	Nov 21 '25	Option Exercise	0.39	35,868	13,989	35,868	Nov 25 06:00 PM

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Ph.D.Dr. Sean P. Bohen M.D.

Chief Legal Officer & Corporate SecretaryMs. Shawnte M. Mitchell J.D.

CFOMr. Jason O'Byrne M.B.A.

Chief Scientific OfficerDr. David C. Myles Ph.D.

Vice President of Corporate CommunicationsMs. Courtney O'Konek

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OLMA

Olema Pharmaceuticals Inc

Upgrade your Finviz experience